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Short communication
CD4+IL-13+ cells in peripheral blood well correlates
with the severity of atopic dermatitis in children
Atopic dermatitis (AD) is a chronic inﬂammatory skin
disease aﬀecting about 15% of children, with consequent
costs and morbidity. The AD has its onset during the ﬁrst
6 months of life in 45%, in the ﬁrst year of life in 60%
and before 5 years in at least 85% of aﬀected children
(1, 2). The criteria proposed by Haniﬁn more than
20 years ago, still maintain their validity for diagnosing
the disease (3). In addition, the severity score atopic
dermatitis (SCORAD) index provides a standardized and
reproducible method to quantify the disease’s severity (4,
5). Nowadays, the exact role of allergy/atopy in the
pathogenesis of AD is still controversial, but it is true that
the immunological mechanisms underlying the disease (6)
somewhere resemble those of other allergic disorders. It is
also well-known that many children with AD are sensi-
tized to inhalant/food allergens, so that AD is called
extrinsic. Many of the abnormalities found in patients
with AD [e.g. increased serum immunoglobulin E (IgE)
and peripheral blood eosinophilia] are considered the
result of a predominant production of Th2 cytokines,
namely interleukin (IL)-4, IL-5 and IL-13 [with concom-
itant reduction of interferon (IFN)-c production] (7–9).
More recently IL-13 has emerged as a pivotal mediator of
Th2-dominant immune responses (10) and also as a
predictive marker of AD development in children (11),
thus supporting that IL-13 plays an important role also in
AD pathogenesis (12). Of note, IL-13 cooperates to many
biological activities of IL-4, another typical Th2 cytokine
(13, 14). In addition, in vivo and in vitro data have shown
that the pattern of cytokine expression correlates with
disease severity (15, 16). In the acute skin lesions of AD
the number of IL-13 mRNA positive cells is usually
higher than in chronic AD and the role of this cytokine
as marker of disease’s activity has been consistently
demonstrated (17).
This study aimed at evaluating the relationship
between clinical and immunological variables, during
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the acute and remission phases of AD. We studied
therefore the production of IL-13 by activated puriﬁed T
cells in order to relate this marker of Th2 predominance
to SCORAD index.
Material and methods
Study design
Twenty children were recruited from an outpatient clinic and their
clinical baseline characteristics are shown in Table 1. All children
fulﬁlled the diagnostic criteria for acute extrinsic AD. At visit 1,
patients had no asthma or rhinitis. The AD children were free of
antihistamines, systemic steroids or topical steroids during the
previous 2 weeks. At visit 2, all children were in remission phase and
cleared of eczema. Ten age-matched children with no family history
for atopy, served as control group (Table 1).
The clinical severity of AD (measured by the SCORAD index)
and several immunological parameters (total serum IgE, blood
eosinophil count, Th1 and Th2 cells) were assessed (visit 1). When a
clinical remission was obtained, with 1–2 week bursts of topical
corticosteroid (mometasone furoate) once-daily (18), the same
parameters were reassessed (visit 2). A washout period of at least
2 weeks from the last application of the topical steroid was elapsed
at visit 2. All parents signed a written informed consent.
Clinical scoring system
The severity of AD was measured through the SCORAD index (4).
The AD was considered as mild if the SCORAD index was <25,
moderate if index was between 25 and 50, and severe form if
SCORAD index was >50. All patients were clinically assessed at
both visits (acute phase – visit 1 and remission phase – visit 2), by
the same supervisor (SLG) trained in SCORAD index evaluation
and unaware of the immunological parameters.
Allergy tests
All patients (including controls) underwent skin prick tests for the
geographically relevant aeroallergens (Dermatophagoides pteronys-
sinus, parietaria pollen, grasses, olive tree, cat/dog dander and
Alternaria alternata) and the most common food allergens (cow
milk, egg, peanut, cod ﬁsh, wheat and soybean). The skin response
was measured according to EAACI criteria (19). Blood samples were
collected at visit 1 (acute phase) and after the clinical remission of
skin lesions (visit 2), for the determination of serum total IgE
(UniCAp Total IgE; Pharmacia, Uppsala, Sweden), serum-speciﬁc
IgE (UniCap Speciﬁc IgE; Pharmacia Upjohn, Uppsala, Sweden),
total white blood cells and eosinophil count. For speciﬁc IgE, a level
of 0.35 kU/l or greater was considered positive. In the control group,
total and speciﬁc IgE assays and eosinophil count were performed.
Cells and cytokines
Puriﬁed T cells, isolated from peripheral blood by Ficoll density
gradient, were stimulated for 4 h with phorbol-12-myristate-
13-acetate (PMA, 25 ng/ml; Sigma, Milan, Italy) and ionomycin
(1 lg/ml; Sigma) in the presence of Brefeldin A (10 lg/ml; Sigma).
After activation, 1 · 106 cells were incubated with peridinin chlo-
rophyll protein (PerCP)-conjugated CD4 monoclonal antibody
(mAb) (30 min). After surface staining and washing, the cells were
permeabilized (1X ﬂow cytometry cell sorter (FACS) Permeabilizing
Solution; Becton Dickinson, San Diego, CA, USA) and stained with
ﬂuorescein conjugate (FITC)- or phycoerythrin conjugate
(PE)-anti-intracellular cytokine antibody and incubated for 30 min
at 4C in the dark. Antihuman FITC-IFN-c, FITC-IL-2, PE-IL-4,
PE-IL-13 mAbs (Becton-Dickinson Pharmingen, San Diego, CA,
USA) were used to evaluate Th1 and Th2 phenotypes. Isotype
matched normal, PerCP, PE and FITC antibodies were used as
negative controls. Cells were analysed by three-colour ﬂow cyto-
metric analysis using FACScalibur (Becton Dickinson).
Statistical analysis
Data are reported as median and range. All the statistical evalua-
tions were performed by tests for nonparametric data. The level of
signiﬁcance was set as P-values <0.05. The statview statistical
software (SAS Institute Inc., Cary, NC, USA) was used for all
statistical computations.
Results
The baseline clinical and laboratory characteristics in the
AD group on admission in the study (acute phase) and in
the control subjects, matched for age and sex, are shown
in Table 1. The overall median SCORAD index was 38.0
(range: 15.3–88.1). The AD was mild in ﬁve (25%)
patients, moderate in 10 (50%); and severe in ﬁve (25%).
All patients had positive skin test for house dust mite
(HDM), and three also displayed skin sensitivity for hen
egg. The skin positive tests were conﬁrmed by the
radioallergosorbent test (RAST) assay. Total serum IgE
levels were increased (>2 SD for age) in 16 of the
20 patients (80%).
A signiﬁcant relationship (P ¼ 0.0001, Spearman rank
correlation) between the eosinophil count and the
Table 1. Clinical and laboratory characteristics of AD patients and control subjects
Patients Mild SCORAD <25 Moderate SCORAD 25–50 Severe SCORAD >50 Total Control subjects
N 5 10 5 20 10
Mean age (years) 5.4 4.1 6.6 5.5
Age range (years) 4–9 2–7 2–9 2–10
Sex (M/F) 2/3 5/5 3/2 10/10 5/5
Total IgE (median and range) 250 (105–334) 185 (90–680) 340 (160–600) 38.5 (23.5–79.0)
Blood eosinophils (median and range) 280 (220–420) 550 (350–950) 950 (830–980) 35.5 (14–72)
RAST to mites (kU/l) (median and range) 3.45 (0.8–16.4) 4.5 (1.1–15.7) 5.6 (1.2–15.2) <0.35
AD, atopic dermatitis; IgE, immunoglobulin E; RAST, radioallergosorbent test; SCORAD, severity score atopic dermatitis.
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SCORAD index value was found in the acute phase as
shown in Fig. 1A. Furthermore, eosinophil count signi-
ﬁcantly decreased during the remission period
(P < 0.0001, Wilcoxon signed rank test, Fig. 1B). No
signiﬁcant diﬀerence in IgE level was found between the
acute and the remission phase, and no correlation was
found between total IgE and eosinophils, total IgE and
SCORAD index (data not shown).
Concerning the distribution of Th1 and Th2 pheno-
types in the acute phase, we found no signiﬁcant diﬀerence
in the percentage of CD4+IFNc+ cells (Th1 cells),
between AD patients and controls (19.9%, 10.1–27.5 vs
20.1, 12.0–29.8, P ¼ ns, Mann–Whitney U-test, Fig. 2A).
However, CD4+IL-4+ cells (Th2 cells) were signiﬁcantly
higher in the AD group than in controls (17.0, 13.7–
21.4% vs 12.8, 6.4–17.2%, P < 0.0001, Fig. 2B).
In the acute phase of AD, we found that the percentage
of CD4+IL-13+ T cells was signiﬁcantly diﬀerent among
the three SCORAD severity classes reaching the higher
levels in severe AD class (P < 0.0001, Kruskall–Wallis
test, Fig. 3A). In fact, the CD4+IL-13+ T cells
were signiﬁcantly correlated to the SCORAD index
(P ¼ 0.0007, Fig. 3B). The percentage of CD4+IL-13+
T cells decreased during clinical remission, and no
signiﬁcant diﬀerence was found among SCORAD sever-
ity classes at remission (P ¼ 0.095, Kruskall–Wallis test,
Fig. 3C). In fact, we found a strong correlation between
DIL-13 (diﬀerence between the acute phase and the
remission phase) and CD4+IL-13+ percentage cells in
the acute phase (P < 0.0001, Spearman rank correla-
tion), as shown in Fig. 3D.
Figure 1. (A) Correlation between atopic dermatitis (AD)
severity score atopic dermatitis (SCORAD) index and blood
eosinophil count in the acute phase (P ¼ 0.0001, Spearman
rank correlation). (B) Absolute eosinophil counts in acute and
remission AD, and in control subjects. Bars indicate (from the
bottom to the top) 10th, 25th, 50th (median), 75th and 90th
percentiles. Values below 10th and above 90th percentiles are
plotted as circles. Diﬀerences between AD acute phase and
remission phase (Wilcoxon signed rank test) and between AD
remission phase and controls (Mann–Whitney U-test) were
signiﬁcant.
Figure 2. (A) Percentages of CD4+IFNc+ cells and
(B) CD4+IL-4+ cells in the acute phase of atopic dermatitis
(AD) and in control subjects. The percentage of CD4+IL-4+
cells in the acute phase of AD was signiﬁcantly higher than in
controls (Mann–Whitney U-test).
CD4+IL-13+ T cells in atopic dermatitis
393
Discussion
The AD is a very common disease of the infancy, and its
association with atopy is well recognized since many years
(6, 7). In fact, in patients with AD, the sensitization to
environmental allergens is frequent, and allergen avoid-
ance strategies may improve the clinical outcome (20).
Nevertheless, despite intensive research a unifying path-
ogenetic concept of AD has not been yet established.
The present study shows that in the acute phase of AD,
a Th2 phenotype predominates as demonstrated by the
relative increase of CD4+IL-4+ and CD4+IL-13+ cells.
Interestingly, CD4+IL-13+ cells exhibited a very strict
correlation with the SCORAD index, and the remission
of clinical symptoms was accompanied by a reduction
of CD4+IL-13+ cells. The levels of CD4+IL-13+ cells
during the acute and the remission phases mirror the
clinical time course of AD. We found a strict correlation
between the number of CD4+IL-13+ cells in the AD
group and the severity of the disease as measured by the
SCORAD index (P ¼ 0.0007). Of note we suggest that
CD4+IL-13+ cell percentages could characterize the
acute phase of AD. Previous attempts to identify the
most reliable marker of disease activity were made.
Several eosinophil-associated parameters (e.g. eosinophi-
lic cationic protein, urinary eosinophil protein X, periph-
eral eosinophilia and IL-5 production) have been
considered good candidates (21, 22). More recently also
selectins and intracellular adhesion molecule (ICAM)-1
(23, 24), which mediate the cellular traﬃc, have
been proposed as hallmark of severity. In this sense,
CD4+IL-13+ cell count could be considered a good
biological marker, since it behaves dynamically according
to the clinical AD course. Indeed, the possible correlation
of IL-13 with severity of AD was suggested since 1997 in
a study comparing children with allergic or nonallergic
asthma and AD (25). It is to be stressed that although the
highest CD4+IL-13+ values are related to a severe AD
SCORAD index at onset of the disease, this does not
appear to predict the subsequent remission. In addition,
the decrease in CD4+IL-13+ percentage is not dependent
on the baseline value.
Our results strongly suggest that in AD a merely
clinical scoring method, as SCORAD is, has an immu-
nological counterpart: in fact, the number CD4+IL-13+
cells is related to the clinical scoring method. Moreover,
Figure 3. (A) CD4+IL-13+ cells in acute atopic dermatitis (AD) distinguished in mild, moderate and severe according to the score
atopic dermatitis (SCORAD) index and in control group. Diﬀerences among severity SCORAD groups and control group were
signiﬁcant (P < 0.0001, Kruskall–Wallis test). Box plots as in Fig. 1B; (B) linear correlation between CD4+IL-13+ cells and AD
SCORAD index (Spearman rank correlation); (C) CD4+IL-13+ cells in the three severity groups in the remission period (diﬀerences
not signiﬁcant); (D) correlation between the delta IL-13 (DIL-13) (percentage of CD4+IL-13+ in the acute phase–remission phase) and
the percentage of CD4+IL-13+ in the acute phase. Signiﬁcant P-values are shown upon the bars. Bars indicate (from the bottom to the
top) 10th, 25th, 50th (median), 75th and 90th percentiles. Values below 10th and above 90th percentiles are plotted as circles.
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the clinical recovery is conﬁrmed by the return of
CD4+IL-13+ percentage towards levels not diﬀerent
from controls. Future approaches in clinically oriented
research will be needed to complete our understanding of
this skin disease.
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